Related Experiment Video
Updated: Aug 23, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Regulation of Molecular Targets in Osteosarcoma Treatment
Betul Celik1,2, Kader Cicek1,2, Andrés Felipe Leal2
1Department of Biological Science, University of Delaware, Newark, DE 19716, USA.
Abstract:
The most prevalent malignant bone tumor, osteosarcoma, affects the growth plates of long bones in adolescents and young adults. Standard chemotherapeutic methods showed poor response rates in patients with recurrent and metastatic phases. Therefore, it is critical to develop novel and efficient targeted therapies to address relapse cases. In this regard, RNA interference technologies are encouraging options in cancer treatment, in which small interfering RNAs regulate the gene expression following RNA interference pathways. The determination of target tissue is as important as the selection of tissue-specific promoters. Moreover, small interfering RNAs should be delivered effectively into the cytoplasm. Lentiviral vectors could encapsulate and deliver the desired gene into the cell and integrate it into the genome, providing long-term regulation of targeted genes. Silencing overexpressed genes promote the tumor cells to lose invasiveness, prevents their proliferation, and triggers their apoptosis. The uniqueness of cancer cells among patients requires novel therapeutic methods that treat patients based on their unique mutations. Several studies showed the effectiveness of different approaches such as microRNA, drug- or chemotherapy-related methods in treating the disease; however, identifying various targets was challenging to understanding disease progression. In this regard, the patient-specific abnormal gene might be targeted using genomics and molecular advancements such as RNA interference approaches. Here, we review potential therapeutic targets for the RNA interference approach, which is applicable as a therapeutic option for osteosarcoma patients, and we point out how the small interfering RNA method becomes a promising approach for the unmet challenge.
Insights
RNA interference offers a promising new avenue for treating osteosarcoma, particularly in recurrent or metastatic cases. This approach utilizes small interfering RNAs to target and silence specific genes, potentially halting tumor growth and spread.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Osteosarcoma is a common bone cancer in young adults, with limited treatment success in advanced stages.
- Current chemotherapy shows poor efficacy for recurrent and metastatic osteosarcoma, necessitating novel therapeutic strategies.
- RNA interference (RNAi) presents a promising gene-silencing approach for cancer therapy.
Purpose of the Study:
- To review potential therapeutic targets for RNA interference (RNAi) in osteosarcoma treatment.
- To explore the application of small interfering RNAs (siRNAs) for targeting patient-specific mutations in osteosarcoma.
- To highlight the potential of siRNA-based therapies for addressing unmet needs in osteosarcoma relapse.
Main Methods:
- Review of current literature on RNA interference technologies in cancer therapy.
- Discussion of gene targets and tissue-specific promoters for osteosarcoma treatment.
- Evaluation of lentiviral vectors for efficient siRNA delivery and long-term gene regulation.
Main Results:
- Silencing overexpressed genes via RNAi can reduce tumor cell invasiveness, proliferation, and induce apoptosis.
- RNAi offers a personalized medicine approach by targeting unique mutations in individual cancer cells.
- Lentiviral vectors facilitate effective cytoplasmic delivery and genomic integration of therapeutic siRNAs.
Conclusions:
- RNA interference, particularly using small interfering RNAs, is a promising therapeutic strategy for osteosarcoma.
- Targeting patient-specific genes with RNAi can overcome challenges in treating recurrent and metastatic disease.
- Further research into specific targets and delivery systems is crucial for clinical application of RNAi in osteosarcoma.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

